Literature DB >> 28100976

Ventricular Tachycardia in Fabry Disease Detected in a 50-Year-Old Woman during 14-Day Continuous Cardiac Monitoring.

Jaime Silva-Gburek, Laura Rochford, Robert Hopkin, John L Jefferies.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder. Female carriers were long thought to be asymptomatic; however, research has revealed the opposite. Cardiac conditions are the chief causes of death in women with Fabry disease. Although ventricular tachycardia has been reported in male patients with Fabry disease, it is not thought to be a frequent finding in females. We describe the case of a 50-year-old woman in whom we used 14-day continuous electrocardiographic monitoring to identify nonsustained ventricular tachycardia, after electrocardiograms and 24-hour Holter monitoring failed to detect the arrhythmia. A permanent implantable cardioverter-defibrillator relieved the patient's symptoms. We discuss why this case supports the need for more extensive electrophysiologic evaluation in women who have Fabry disease.

Entities:  

Keywords:  Alpha-galactosidase/blood; Fabry disease/complications/epidemiology; arrhythmias, cardiac/etiology; defibrillators, implantable; female; prevalence; tachycardia, ventricular/diagnosis/etiology/prevention & control; treatment outcome

Mesh:

Substances:

Year:  2016        PMID: 28100976      PMCID: PMC5179162          DOI: 10.14503/THIJ-15-5572

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  9 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

Authors:  Raymond Y Wang; Alicia Lelis; James Mirocha; William R Wilcox
Journal:  Genet Med       Date:  2007-01       Impact factor: 8.822

Review 3.  Arrhythmias in Fabry cardiomyopathy.

Authors:  Deepak Acharya; Harish Doppalapudi; José A Tallaj
Journal:  Card Electrophysiol Clin       Date:  2015-04-01

4.  Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Authors:  Jaymin S Shah; Derralynn A Hughes; Bhavesh Sachdev; Maite Tome; Deirdre Ward; Philip Lee; Atul B Mehta; Perry M Elliott
Journal:  Am J Cardiol       Date:  2005-09-15       Impact factor: 2.778

5.  Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease.

Authors:  Osamu Igawa; Junichiro Miake; Ichiro Hisatome
Journal:  Pacing Clin Electrophysiol       Date:  2005-10       Impact factor: 1.976

6.  Arrhythmias in Fabry cardiomyopathy.

Authors:  Deepak Acharya; Peter Robertson; G Neal Kay; Leslie Jackson; David G Warnock; Vance J Plumb; José A Tallaj
Journal:  Clin Cardiol       Date:  2012-08-09       Impact factor: 2.882

7.  Clinical features of Fabry's disease in Australian patients.

Authors:  J Galanos; K Nicholls; L Grigg; L Kiers; A Crawford; G Becker
Journal:  Intern Med J       Date:  2002-12       Impact factor: 2.048

Review 8.  The heart in Fabry's disease.

Authors:  Mary N Sheppard
Journal:  Cardiovasc Pathol       Date:  2009-11-17       Impact factor: 2.185

9.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

  9 in total
  1 in total

Review 1.  Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review.

Authors:  Daniel Oder; Jonas Müntze; Peter Nordbeck
Journal:  Cardiovasc Diagn Ther       Date:  2021-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.